JP2023536815A - 好中球駆動性炎症性病変の治療方法 - Google Patents

好中球駆動性炎症性病変の治療方法 Download PDF

Info

Publication number
JP2023536815A
JP2023536815A JP2023505850A JP2023505850A JP2023536815A JP 2023536815 A JP2023536815 A JP 2023536815A JP 2023505850 A JP2023505850 A JP 2023505850A JP 2023505850 A JP2023505850 A JP 2023505850A JP 2023536815 A JP2023536815 A JP 2023536815A
Authority
JP
Japan
Prior art keywords
therapeutic peptide
seq
svl4
neutrophil
structured polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023505850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536815A5 (enExample
Inventor
エギンク，ローラ・エル
フーバー，ジェイ・ケネス
Original Assignee
スサヴィオン バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スサヴィオン バイオサイエンシーズ インコーポレイテッド filed Critical スサヴィオン バイオサイエンシーズ インコーポレイテッド
Publication of JP2023536815A publication Critical patent/JP2023536815A/ja
Publication of JP2023536815A5 publication Critical patent/JP2023536815A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023505850A 2020-07-28 2021-06-24 好中球駆動性炎症性病変の治療方法 Withdrawn JP2023536815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057741P 2020-07-28 2020-07-28
US63/057,741 2020-07-28
PCT/US2021/038999 WO2022026092A2 (en) 2020-07-28 2021-06-24 Method of treatment of neutrophil-driven inflammatory pathologies

Publications (2)

Publication Number Publication Date
JP2023536815A true JP2023536815A (ja) 2023-08-30
JP2023536815A5 JP2023536815A5 (enExample) 2024-06-28

Family

ID=80038122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505850A Withdrawn JP2023536815A (ja) 2020-07-28 2021-06-24 好中球駆動性炎症性病変の治療方法

Country Status (7)

Country Link
US (1) US20230285505A1 (enExample)
EP (1) EP4181942A4 (enExample)
JP (1) JP2023536815A (enExample)
CN (1) CN116194143A (enExample)
AU (1) AU2021318793A1 (enExample)
CA (1) CA3185526A1 (enExample)
WO (1) WO2022026092A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768650T3 (pl) * 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
WO2023183059A1 (en) * 2022-03-24 2023-09-28 Susavion Biosciences, Inc. Method of treatment of neutrophil-driven inflammatory pathologies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
WO2013096829A2 (en) * 2011-12-22 2013-06-27 Arizona Biomedical Research Commission Activation of cellular assault processes in the treatment of glioblastoma multiforme
US9155796B2 (en) * 2012-12-04 2015-10-13 Susavion Biosciences, Inc. Hydrogels with covalently linked polypeptides
CA2971471C (en) * 2014-12-19 2023-04-18 Susavion Biosciences, Inc. Immunotherapy treatments and compositions
EP3288576A4 (en) * 2015-04-27 2019-01-16 Susavion Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND PERSISTENT VIRUS INFECTIONS
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
AU2019205279A1 (en) * 2018-01-08 2020-07-30 Susavion Biosciences, Inc. Compositions and methods of treating cancer with glycomimetic peptides

Also Published As

Publication number Publication date
US20230285505A1 (en) 2023-09-14
CA3185526A1 (en) 2022-02-03
EP4181942A4 (en) 2024-10-02
WO2022026092A2 (en) 2022-02-03
AU2021318793A1 (en) 2023-02-09
WO2022026092A3 (en) 2022-03-03
WO2022026092A9 (en) 2022-04-28
CN116194143A (zh) 2023-05-30
EP4181942A2 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
Jiang et al. Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis
RU2429004C2 (ru) Способы регуляции медиаторов воспаления и пептиды, используемые в них
US8455435B2 (en) Remedies for ischemia
Liu et al. Effective-components combination improves airway remodeling in COPD rats by suppressing M2 macrophage polarization via the inhibition of mTORC2 activity
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
CN104159594A (zh) 用于皮肤病治疗的凯莫瑞c15肽的局部制剂
Ahn et al. Transient receptor potential channel TRPV4 mediates TGF-β1-induced differentiation of human ventricular fibroblasts
Lai et al. Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: Evaluation for preventive, therapeutic, and Recurrent management of psoriasis
US11213567B2 (en) ZAG-derived peptide and use thereof
US20230285505A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
CN104507487A (zh) 使用Serelaxin治疗炎症
WO2013104928A1 (en) Peptide and uses thereof
CN119925565A (zh) 一种多肽在制备治疗银屑病药物中的应用
US20200376138A1 (en) Lipid nano particle complex comprising aptide fused with cell penetrating materials and use same
US20260055139A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
HK40090910A (en) Method of treatment of neutrophil-driven inflammatory pathologies
US20250222064A1 (en) Method of treatment of neutrophil-driven inflammatory pathologies
CN119546297A (zh) 用于抑制免疫应答的到手香提取物
US9839671B2 (en) Peptide and uses therefor
Schoen et al. Anti-RANKL nanobody ALX-0141 shows sustained biomarker inhibition in a phase I study in healthy postmenopausal women
Weyer et al. Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis
ES2932076T3 (es) Moduladores agonistas de los receptores de glucocorticoides selectivos (SEGRAM) no esteroideos y usos de los mismos
아지즈 GPCR19 agonist (TDCA) efficacy and mode of action in atopic dermatitis and rosacea
Popov Development of inhaled CaSR NAMs for the treatment of pulmonary disorders
JP2026501583A (ja) 非糖尿病加齢マウスにおいて創傷の治癒を促進するためのＨｏｘＡ３治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240620

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250327